AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 51 min read$BCDA

Altman Peter purchased $872 of BCDA

Altman Peter (President and CEO) purchased 800 shares of BioCardia, Inc. (BCDA) at $1.09 on 2026-09-03.

Original reporting
SEC EDGAR · Altman Peter
Published Sep 5, 2026, 1:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 5, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BCDA
Neutral
high confidence
Mentioned
$BCDA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDANeutralLow
01

Why it matters

The purchase is unlikely to move the stock price or affect investor sentiment.

02

Market read

Minor insider purchase with negligible market impact.

03

What to watch

Potential upcoming clinical data could make the purchase more meaningful, but not disclosed.

Relevance 4/10Novelty 3/10Timing: post‑filing on 2026‑09‑04

Background

Form 4 filings disclose insider transactions; traders monitor large purchases for signals.

Company-level read

Ticker impact

$BCDANeutralHigh confidence
Context

CEO Peter Altman bought 800 shares for $872 in an open‑market purchase.

Expected impact

No material move expected.

Evidence & confidence

The transaction size is trivial relative to market cap and typical trading volume.

Market effects

Sector

None; BioCardia operates in a niche biotech segment.

Regional

No regional effect.

Global

Insignificant.

Counterpoint

What could challenge this read

Even small insider buys can signal confidence, but the amount is too small to act on.

Key entities

  • Person
    Peter Altman

    President and CEO of BioCardia, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCDA insider trading history →

Related articles

AUG 19
$BCDAMed

BioCardia (BCDA) Q2 2026 Earnings Call Transcript

BioCardia (BCDA) reported Q2 2026 earnings with $4.1M in cash, a net loss of $1.6M, and raised $4.9M via ATM facility. The company reduced R&D spending and is progressing with regulatory submissions for CardiAMP in Japan and the U.S. Management anticipates market approval in Japan by Q4 2027 and FDA premarket approval support from ongoing trials. BioCardia is also exploring partnerships and streamlining trials to enhance enrollment.

fool.com3 min
AUG 13
$BCDAMed

BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan

BioCardia (BCDA) reported Q2 2026 regulatory updates for its CardiAMP cell therapy and Helix delivery catheter. According to management, Japan’s PMDA supported a Shonin premarket submission, with approval expected about 12 months after filing. The FDA said CardiAMP Heart Failure 2 could support premarket approval and outlined two Helix clearance pathways. Q2 2026 net cash used in operations was ~$1.7M; cash ended at ~$5.4M.

yahoo.com4 min
AUG 12
$BCDAMed

BioCardia, Inc. (BCDA): Results of Operations and Financial Condition

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results Sunnyvale, Calif. – August 12, 2026 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,

SEC EDGAR 8-K6 min